RISE-PD Full Data Highlight IPX203’s Impact as Promising Parkinson Treatment

[Farooqji]

neurologylive.com/view/rise...

[park_bear]

extended-release carbidopa-levodopa (CD/LD)

[Smittybear7 in reply to park_bear]

????

[Esperanto in reply to park_bear]

Indeed, it seems like old wine in new bottles. Moreover, the comparison with IR CD-LD is comparing apples with oranges. One would think that a comparison with ER CD-LD would make more sense, but of course the outcome would then be somewhat less spectacular. Yet the following study shows that when comparing with Rytary, there is indeed an interesting difference, because IPX203 has a significantly longer pharmacodynamic effect.

journals.lww.com/clinicalne...

[park_bear in reply to Esperanto]

I hate how this company has polluted the terminology by labeling this as yet another version of ER.

That aside, more levodopa options are a good thing.

[Buckholt]

Worry is that cost will be high making insurers reluctant in the US and unavailable in UK. Only useful if available

[Esperanto in reply to Buckholt]

One of the few advantages of the market forces is that they must still be somewhat competitive compared to the other ER CD-LD medicines. So maybe available anyway. It would be a major improvement for intake periods longer than 5 hours.